PHARMACOLOGY

Indication

This drug is used alone or with concomitant antacids for the following conditions: short-term
treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison
syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid
levels. It also used in the short term treatment of active benign gastric ulcers and maintenance
therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for
the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed)
11,12
and the maintenance of gastric or duodenal ulcer healing.

Associated Conditions View As Table

Acid Aspiration Syndrom

Ankylosing Spondylitis (AS

Duodenal Ulce

Erosive Esophagiti

Gastric Ulce

Gastric hypersecretio

Gastro-esophageal Reflux Disease (GERD

Healin

Heartbur

Osteoarthritis (OA

Peptic Ulcer Diseas

Rheumatoid Arthriti

Stress Ulcer

Zollinger-Ellison Syndrom

Active duodenal ulcer

Benign gastric ulcer healin

Benign gastric ulcer

Duodenal ulcer healin

Post-operative peptic ulce

Recurrent hemorrhage from bleeding ulcer

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

LEARN MOR

Pharmacodynamics

Ranitidine decreases the secretion of gastric acid stimulated by food and drugs. It also reduces
6,11
the secretion of gastric acid in hypersecretory conditions such as Zollinger-Ellison syndrome.
Marked improvements in the appearance of the esophageal tissues have been observed by
5,11
endoscopic imaging a er ranitidine therapy.

Mechanism of action

A er a meal, the hormone gastrin, produced by cells in the lining of the stomach, stimulates the
release of histamine, which then binds to histamine H2 receptors, leading to the secretion of
gastric acid. Ranitidine reduces the secretion of gastric acid by reversible binding to histamine
 Adverse Effects

Learn about our commercial Adverse Effects data.

LEARN MOR

Toxicity

Oral doses of 1,000 mg/kg in mice and rats were not found to be lethal. Intravenous LD50 values
in mice and rats were 77 and 83 mg/kg, respectively.12

Overdose information

There has been limited experience with ranitidine overdose. Reported acute ingestions of up to 18
grams orally were followed by temporary adverse effects similar to the normal adverse effects of
this drug, including tachycardia, bradycardia, dizziness, diarrhea, nausea, and vomiting, among
other effects.12 Gait abnormalities and hypotension have also been observed. When an overdose
with ranitidine is suspected, remove unabsorbed ranitidine from the gastrointestinal tract if
11,13
possible, and monitor the patient and provide supportive therapy as required.

Affected organisms

Humans and other mammals

Pathways

Ranitidine Action Pathwa

Drug action

Pharmacogenomic Effects/ADRs

Not Available

INTERACTIONS

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are
experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not
necessarily mean no interactions exist.

APPROVED

VET APPROVED

NUTRACEUTICAL

ILLICIT

WITHDRAWN

INVESTIGATIONAL

EXPERIMENTAL

ALL DRUGS

DRUG INTERACTION

UNLOCK ADDITIONAL DATA

Generic Prescription Products
NAME DOSAGE STRENGTH ROUTE LABELLER MARKETING START MARKETING END

UNLOCK ADDITIONAL DATA

Ag-ranitidine Tablet Oral Angita Pharma Inc. Not applicable Not applicable

Ag-ranitidine Tablet Oral Angita Pharma Inc. 2019-08-14 Not applicable

Apo-ranitidine Solution Oral Apotex Corporation 2006-07-14 Not applicable

Apo-ranitidine Tablet 150mg Tablet Oral Apotex Corporation 1987-12-31 Not applicable

Apo-ranitidine Tablet 300mg Tablet Oral Apotex Corporation 1987-12-31 Not applicable

Dom-ranitidine Tablet Oral Dominion Pharmacal 2001-03-22 Not applicable

Dom-ranitidine Tablet Oral Dominion Pharmacal 2001-03-22 Not applicable

Good Sense Acid Reducer Tablet 75 mg/1 Oral bryant ranch prepack 2009-05-21 Not applicable

Jamp-ranitidine Tablet Oral Jamp Pharma Corporation 2018-10-24 Not applicable

Jamp-ranitidine Tablet Oral Jamp Pharma Corporation 2018-10-24 Not applicable

Unapproved/Other Products

MARKETING MARKETING
NAME INGREDIENTS DOSAGE ROUTE LABELLER START END
 Over the Counter Products
MARKETING MARKETING
NAME DOSAGE STRENGTH ROUTE LABELLER START END

UNLOCK ADDITIONAL DATA

7 Select Acid Tablet, film 150 mg/1 Oral 7-Eleven 2014-04-22 2020-11-30
Reducer coated

Acid Reducer Tablet, film 75 mg/1 Oral Nucare Pharmaceuticals,inc. 2018-10-01 Not
coated applicable

Acid Reducer Tablet, film 75 mg/1 Oral Winco Foods 2012-08-02 Not
coated applicable

Acid Reducer Tablet, film 75 mg/1 Oral Good Sense 2013-10-11 Not
coated applicable

Acid Reducer Tablet 150 mg/1 Oral Mc Kesson 2014-01-07 Not

applicable

Acid Reducer Tablet 75.0 mg Oral Stanley Pharmaceuticals, A Division Of Vita Health 2000-03-27 2004-07-26
Products Inc.

Acid Reducer Tablet 150 mg/1 Oral Shopko Stores Operating 2013-06-05 2015-11-27

Acid Reducer Tablet, film 75 mg/1 Oral Ohm Laboratories Inc. 2012-07-10 2019-09-11
coated

Acid Reducer Tablet, film 75 mg/1 Oral Preferred Plus (Kinray) 2014-01-27 Not
coated applicable

Acid Reducer Tablet 75 mg/1 Oral Hyvee 2009-11-23 2014-12-02

Mixture Products
MARKETING MARKETING
NAME INGREDIENTS DOSAGE ROUTE LABELLER START END

DeramsilkRx Ranitidine hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) Kit Oral; Patchwerx 2015-06-12 Not
Anodynexa Pak + Diclofenac sodium (75 mg/1) Topical Labs applicable
 08 01

DermacinRx Ranitidine hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) Kit Oral; PureTek 2015-06-12 2019-03-05
Inflammatral Pak + Diclofenac sodium (75 mg/1) Topical Corporation

Inflammation Ranitidine hydrochloride (150 mg/1) + Diclofenac sodium (75 mg/1) + Kit Oral; Tmig, Inc. 2015-08-18 Not
Reduction Pack Lidocaine (25 mg/1g) + Prilocaine (25 mg/1g) Topical applicable

Ranitidine hydrochloride (4.2 g/4.2g)

 Histamine Antagonists

Histamine H2 Antagonist

OAT1/SLC22A6 inhibitor

OAT1/SLC22A6 Substrate

OAT3/SLC22A8 Substrate

OCT1 inhibitor

OCT1 substrate

OCT2 Inhibitor

OCT2 Substrate

P-glycoprotein inhibitor

P-glycoprotein substrate

Classification

Not classified

CHEMICAL IDENTIFIERS

UNII

884KT10YB

CAS number

66357-35-5

InChI Key

VMXUWOKSQNHOCA-UHFFFAOYSA-N

InChI
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3

IUPAC Name
[1-({2-[({5-[(
dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}amino)-2-nitroethenyl](methyl)amine

SMILES
CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O

REFERENCES

Synthesis Reference

John W. Clitherow, "Intermediates in the preparation of ranitidine." U.S. Patent US4413135, issued
November, 1981.
US441313

General References

1. Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F: Mania associated with ranitidine: a
case report and review of literature. Fundam Clin Pharmacol. 2016 Aug;30(4):294-6. doi: 10.1111/fcp.12201. Epub 2016 May 5.
PubMed:2708338 ]
2. Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and
therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-198937060-00003.
PubMed:266793 ]
3. Pettit M: Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7.
PubMed:1634194 ]
 4. Badillo R, Francis D: Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014 Aug
6;5(3):105-12. doi: 10.4292/wjgpt.v5.i3.105. [PubMed:2513303
]
5. Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R: Ranitidine therapy for gastroesophageal reflux disease. Results of a large
double-blind trial. Arch Intern Med. 1987 Aug;147(8):1485-91.PubMed:330767
[ ]
6. Vezzadini P, Bonora G, Tomassetti P, Pazzaglia M, Labo G: Medical treatment of Zollinger-Ellison syndrome with ranitidine. Int J Tissue
React. 1983;5(4):339-43.
PubMed:632333
[ ]
7. Roberts CJ: Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet. 1984 May-Jun;9(3):211-21. doi: 10.2165/00003088-198409030-00003.
PubMed:632958 ]
8. Gschwend MH, Guserle R, Erenmemisoglu A, Martin W, Tamur U, Kanzik I, Hincal AA: Pharmacokinetics and bioequivalence study of
ranitidine film tablets in healthy male subjects. Arzneimittelforschung. 2007;57(6):315-9. doi: 10.1055/s-0031-1296625.
PubMed:1768807][
9. Caitlin C. Nugent; Jamie M. Terrell (2018). H2 Blockers- StatPearls. StatPearls Publishing.
10. FDA drug approval package: Zantac Lin ][
11. FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injectionLin ] [
12. GlaxoSmithKline Canada Inc. Product Monograph: Zantac (ranitidine)Lin ] [
13. Ranitidine product monograph Lin []
14. Zantac injection FDA label Fil[ ]
15. Zantac Canadian Monograph Fil ][

External Links

Human Metabolome Database

HMDB000193

KEGG Drug

D0042

PubChem Compound

300105

PubChem Substance

4650554

ChemSpider

486

BindingDB

5010350

RxNav

914

ChEBI

9224

ChEMBL

CHEMBL179004

Therapeutic Targets Database

DAP00034

PharmGKB

PA45122

Guide to Pharmacology

GtP Drug Pag

RxList

RxList Drug Pag

Drugs.com

Drugs.com Drug Pag

Wikipedia

Ranitidin
Water Solubility

0.0795 mg/mL

ALOGPS

logP

0.79

ALOGPS

logP

0.99

ChemAxon

logS

-3.6

ALOGPS

pKa (Strongest Basic)

7.8

ChemAxon

Physiological Charge

ChemAxon

Hydrogen Acceptor Count

ChemAxon

Hydrogen Donor Count

ChemAxon

Polar Surface Area

83.58 Å2

ChemAxon

Rotatable Bond Count

10

ChemAxon

Refractivity

94.15 m3·mol-1

ChemAxon

Polarizability

33.78 Å3

ChemAxon

Number of Rings

ChemAxon

Bioavailability

ChemAxon

Rule of Five

Yes

ChemAxon

Ghose Filter
Histamine H2 receptor

Molecular Weight

40097.65Da

References

1. Pattichis K, Louca LL: Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Drug
Metabol Drug Interact. 1995;12(1):1-36.PubMed:755499
[ ]
2. Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties
and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-
198937060-00003. PubMed:266793
[ ]
3. FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injectionLin ] [

2. Acetylcholinesteras

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Inhibitor

Curator comments

The FDA label indicates that ranitidine is not an anticholinergic agent, likely because its weak anticholinergic effects
observed in studies do not result in clinical effects.

General Function

Serine hydrolase activity

Specific Function

Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the
synaptic cle . Role in neuronal apoptosis.

Gene Name

ACHE

Uniprot ID

P2230

Uniprot Name

Acetylcholinesterase

Molecular Weight

67795.525Da

References

1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in
vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. doi: 10.1002/jat.1036. [
PubMed:1566902 ]
2. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V: The inhibition of acetylcholinesterase by ranitidine: a study on the guinea
pig ileum. J Pharmacobiodyn. 1986 Nov;9(11):941-5. PubMed:355988
[ ]
3. Aono M, Moriga M, Mizuta K, Narusawa H: Cholinergic effects of histamine-H2 receptor antagonists partly through inhibition of
acetylcholinesterase. Gastroenterol Jpn. 1986 Jun;21(3):213-9. doi: 10.1007/bf02774563.
PubMed:287409
[ ]
4. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist
 drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93.
PubMed:809573
[ ]
Lin ] [
5. FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection

ENZYMES

1. Cytochrome P450 1A

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Substrate Inhibitor

Curator comments

Data supporting this enzyme action are limited to in vitro studies.

General Function

Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or
flavoprotein as one donor, and incorporation of one atom of oxygen

Specific Function

Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an
NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...

Gene Name

CYP1A2

Uniprot ID

P0517

Uniprot Name

Cytochrome P450 1A2

Molecular Weight

58293.76Da

References

1. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA: Comparative in vitro and in vivo
inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999
PubMed:1022377
Apr;65(4):369-76. doi: 10.1016/S0009-9236(99)70129-3. [ ]
2. Zhou Q, Yan XF, Zhang ZM, Pan WS, Zeng S: Rational prescription of drugs within similar therapeutic or structural class for
gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov
14;13(42):5618-28.[PubMed:1794893]

2. Cytochrome P450 2D
Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Inhibitor

Curator comments

Data regarding this enzyme action are limited to in vitro studies and show weak inhibition,

General Function

Steroid hydroxylase activity

Specific Function

Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the
metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...

Gene Name

CYP2D6

Uniprot ID

P1063

Uniprot Name

Cytochrome P450 2D6

Molecular Weight

55768.94Da

References

1. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA: Comparative in vitro and in vivo
inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999
Apr;65(4):369-76. doi: 10.1016/S0009-9236(99)70129-3.
PubMed:1022377
[ ]
2. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP:
Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol. 2010 Jun 1;28(16):2768-76. doi:
10.1200/JCO.2009.23.8931. Epub 2010 May[PubMed:2043962
3. ]
3. Flockhart Table of Drug InteractionsLin
[ ]

3. Cytochrome P450 3A

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Inhibitor

Curator comments

Data limited to one in vitro study, with results showing weak inhibition and likely to have little clinical significance.
General Function

Vitamin d3 25-hydroxylase activity

Specific Function

Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an
NADPH-dependent electron transport pathway. It performs a variety of oxidation react...

Gene Name

CYP3A4

Uniprot ID

P0868

Uniprot Name

Cytochrome P450 3A4

Molecular Weight

57342.67Da

References

1. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA: Comparative in vitro and in vivo
inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999
PubMed:1022377
Apr;65(4):369-76. doi: 10.1016/S0009-9236(99)70129-3. [ ]
2. Ranitidine drug summaryLin[ ]
Lin ] [
3. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers

4. Acetylcholinesteras

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Inhibitor

Curator comments

Though ranitidine has been found to weakly inhibit acetylcholinesterase, the FDA label mentions that it is not an
anticholinergic agent.

General Function

Serine hydrolase activity

Specific Function

Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the
synaptic cle . Role in neuronal apoptosis.

Gene Name

ACHE

Uniprot ID

P2230

Uniprot Name

Acetylcholinesterase
 Acetylcholinesterase

Molecular Weight

67795.525Da

References

1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in
vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. doi: 10.1002/jat.1036.
PubMed:1566902
[ ]
2. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist
drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93. [
PubMed:809573 ]
3. Aono M, Moriga M, Mizuta K, Narusawa H: Cholinergic effects of histamine-H2 receptor antagonists partly through inhibition of
acetylcholinesterase. Gastroenterol Jpn. 1986 Jun;21(3):213-9. doi: 10.1007/bf02774563. [
PubMed:287409 ]
4. FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection Lin []

TRANSPORTERS

1. Solute carrier family 22 member

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Substrate Inhibitor

General Function

Secondary active organic cation transmembrane transporter activity

Specific Function

Translocates a broad array of organic cations with various structures and molecular weights including the model
compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...

Gene Name

SLC22A1

Uniprot ID

O1524

Uniprot Name

Solute carrier family 22 member 1

Molecular Weight

61153.345Da

References

1. Meyer MJ, Seitz T, Brockmoller J, Tzvetkov MV: Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of
ranitidine. PLoS One. 2017 Dec 13;12(12):e0189521. doi: 10.1371/journal.pone.0189521. eCollection 2017. [
PubMed:2923675 ]
2. Han TK, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KL, Thakker DR: Organic cation transporter 1 (OCT1/mOct1) is
localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol. 2013 Aug;84(2):182-9. doi:
10.1124/mol.112.084517. Epub 2013 May [16.PubMed:2368063]
2. P-glycoprotein

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Substrate Inhibitor

General Function

Xenobiotic-transporting atpase activity

Specific Function

Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.

Gene Name

ABCB1

Uniprot ID

P0818

Uniprot Name

Multidrug resistance protein 1

Molecular Weight

141477.255Da

References

1. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics.
Pharm Res. 2000 Dec;17(12):1456-60. PubMed:1130395
[ ]
2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of
PubMed:1295418
heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [ ]
3. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G: Modulation of the permeability of H2 receptor antagonists cimetidine and
ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999 Jan;288(1):171-
8. [PubMed:986276]
4. Dou L, Mai Y, Madla CM, Orlu M, Basit AW: P-glycoprotein expression in the gastrointestinal tract of male and female rats is
influenced differently by food. Eur J Pharm Sci. 2018 Oct 15;123:569-575. doi: 10.1016/j.ejps.2018.08.014. Epub 2018 Aug 15.
PubMed:3011885]

3. Solute carrier family 22 member

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Actions
Substrate

Curator comments

Data for this transporter are limited to the results of an in vitro study.

General Function

Sodium-independent organic anion transmembrane transporter activity

Specific Function

Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the
brain and kidney. Involved in the transport basolateral of steviol, fexofenad...

Gene Name

SLC22A8

Uniprot ID

Q8TCC

Uniprot Name

Solute carrier family 22 member 8

Molecular Weight

59855.585Da

References

1. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug
interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol
Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov PubMed:1629187
16. [ ]
2. Torres AM: Renal elimination of organic anions in cholestasis. World J Gastroenterol. 2008 Nov 21;14(43):6616-21. doi:
10.3748/wjg.14.6616.[PubMed:1903496 ]
3. Kusuhara H, Sugiyama Y: Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx. 2005 Jan;2(1):73-
85. doi: 10.1602/neurorx.2.1.73.
[PubMed:1571705 ]

4. Solute carrier family 22 member

Kind

Protein

Organism

Humans

Pharmacological action
Unknown

Actions
Substrate

General Function

Quaternary ammonium group transmembrane transporter activity

Specific Function

Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine,
noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...

Gene Name

SLC22A2

Uniprot ID

O1524
 O15244

Uniprot Name

Solute carrier family 22 member 2

Molecular Weight

62579.99Da

References

1. Meyer MJ, Seitz T, Brockmoller J, Tzvetkov MV: Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of
ranitidine. PLoS One. 2017 Dec 13;12(12):e0189521. doi: 10.1371/journal.pone.0189521. eCollectionPubMed:2923675
2017. [ ]
2. Nies AT, Schwab M: Organic cation transporter pharmacogenomics and drug-drug interaction. Expert Rev Clin Pharmacol. 2010
Nov;3(6):707-11. doi: 10.1586/ecp.10.60. [
PubMed:2211177 ]
3. Straight Healthcare: OCT2 Lin
[ ]

Drug created on June 13, 2005 07:24 / Updated on January 16, 2021 12:52

Stay up-to-date with the latest from DrugBank!

En

SUBSCRIBE

About

About DrugBank Onlin

Blo

Wishart Research Grou

Career

Terms of Us

Privacy Polic

Support

Help Cente

DrugBank Online FAQ

Contact Suppor

Commercial Dat

Clinical Drug Dat

Scientific Drug Dat

Contact Sale
Website design by Educe Design & Innovation Inc.